10/18/2024

Janusmed sex and gender

Janusmed sex and gender – cilastatin sodium

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Imipenem

Imipenem

Class : A

Show all info

Print

Contact us

  1. Vural S, Erdem E, Gulec SG, Yildirmak Y, Kebudi R. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatr Int. 2010;52:262-7.

  2. Dailly E, Kergueris MF, Pannier M, Jolliet P, Bourin M. Population pharmacokinetics of imipenem in burn patients. Fundam Clin Pharmacol. 2003;17:645-50.

  3. Heikkilä A, Renkonen OV, Erkkola R. Pharmacokinetics and transplacental passage of imipenem during pregnancy. Antimicrob Agents Chemother. 1992;36:2652-5.

  4. Merrem IV (meropenem). DailyMed [www]. US National Library of Medicine. [updated 2016-07-27, cited 2016-08-17].

  5. Sahuquillo-Arce JM, Selva M, Perpiñán H, Gobernado M, Armero C, López-Quílez A et al. Antimicrobial resistance in more than 100,000 Escherichia coli isolates according to culture site and patient age, gender, and location. Antimicrob Agents Chemother. 2011;55:1222-8.

  6. Baran G, Erbay A, Bodur H, Ongürü P, Akinci E, Balaban N et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis. 2008;12:16-21.

  7. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.]

  1. Vural S, Erdem E, Gulec SG, Yildirmak Y, Kebudi R. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatr Int. 2010;52:262-7.
  2. Dailly E, Kergueris MF, Pannier M, Jolliet P, Bourin M. Population pharmacokinetics of imipenem in burn patients. Fundam Clin Pharmacol. 2003;17:645-50.
  3. Heikkilä A, Renkonen OV, Erkkola R. Pharmacokinetics and transplacental passage of imipenem during pregnancy. Antimicrob Agents Chemother. 1992;36:2652-5.
  4. Merrem IV (meropenem). DailyMed [www]. US National Library of Medicine. [updated 2016-07-27, cited 2016-08-17].
  5. Sahuquillo-Arce JM, Selva M, Perpiñán H, Gobernado M, Armero C, López-Quílez A et al. Antimicrobial resistance in more than 100,000 Escherichia coli isolates according to culture site and patient age, gender, and location. Antimicrob Agents Chemother. 2011;55:1222-8.
  6. Baran G, Erbay A, Bodur H, Ongürü P, Akinci E, Balaban N et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis. 2008;12:16-21.
  7. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.]